Phase 2 N=4 Miltefosine to Treat Mucocutaneous Leishmaniasis
Mucosal Leishmaniasis · Cutaneous Leishmaniasis
Primary: Number of Participants With Clinical Cure of Lesions — 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=437 Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia.
Cutaneous Leishmaniasis
Primary: Complete Clinical Response — 85; 103; 86 participants
Phase 2 N=92 Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World
Cutaneous Leishmaniasis
Primary: Complete Clinical Response (CCR) of Lesion at Days 50, 100 and 180 (+7 Days) — 47; 30; 3; 12 Participants
Phase 2 N=414 Sodium Stibogluconate Treatment of Leishmaniasis
Leishmaniasis
Primary: The Primary Safety Endpoint - Frequency of Complications of Therapy — 414 participants
Phase 2 N=77 Use of Sodium Stibogluconate as a Treatment for Leishmaniasis
Leishmaniasis
Primary: Number of Participants That Discontinued Due to Adverse Experience, by Type of Adverse Experience — 12; 10; 3; 1 Participants
Phase 2 N=48 A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous Leishmaniasis
Old World Cutaneous Leishmaniasis
Primary: Safety: Overview of Adverse Events — 16; 7; 0; 0 Participants
Phase 3 N=399 Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama
Cutaneous Leishmaniasis
Primary: Percent of Participants With Final Clinical Cure — 78.6; 77.8 percent of participants
Phase 3 N=375 Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)
Cutaneous Leishmaniasis
Primary: Final Clinical Cure Rate — 101; 102; 73 participants — p=0.0001
Phase 2 N=45 A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis
Cutaneous Leishmaniasis
Primary: Date of Clinical Cure — 2; 2; 15; 10 participants
N/A N=150 Evaluation of CL Detect™ Rapid Test to Detect Cutaneous Leishmaniasis
Skin Diseases
Primary: True Positive — 0 samples
Phase 2 N=56 Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis
Cutaneous Leishmaniasis
Primary: Equivalence of Efficacy Assessed by the Number of Participants With Clinical Cure — 22; 18; 5; 9 Participants
Phase 2 N=30 Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama
Leishmaniasis, Cutaneous
Primary: Number of Participants Who Obtained Final Clinical Cure of Index Lesion — 9; 13 Participants
Phase 2 N=30 Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK)
Leishmaniasis, Cutaneous
Primary: Final Clinical Cure for Index Lesions — 11; 9 participants
Phase 3 N=74 Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study
Visceral Leishmaniosis · HIV-infection/Aids
Primary: Probability of Relapse-free Survival — 79; 71 percentage probability
Phase 2 N=9 Treatment of Oral Premalignant Lesions With 5-ALA PDT
Leukoplakia · Erythroplakia
Primary: Maximum Tolerated Dose — 8 J/cm2
Phase 2 N=14 Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity
Kaposi´s Sarcoma
Primary: Number of Participants With Complete Response — 1; 3 participants
Phase 2 N=118 Randomized Trial of Liposomal Amphotericin B for Histoplasmosis in AIDS Patients
Histoplasmosis · AIDS
Primary: Clinical Response — 32; 25; 28 Participants
N/A N=168 Evaluation of a Rapid Diagnostic Device, CL Detect, for the Diagnosis of Cutaneous Leishmaniasis in Tunisia
Skin Diseases, Parasitic
Primary: Positive Result Comparison: CL Detect Rapid Test With Microscopy and Culture Results — 147; 144; 96 Participants
Phase 2 N=29 Dexamethasone Solution and Dexamethasone in Mucolox™
Oral Lichen Planus · Mucous Membrane Pemphigoid · Pemphigus Vulgaris
Primary: Mean Change From Baseline in Oral Pain Scores on the Visual Analog Scale (VAS) at 4 Weeks — 6.3; 4.4 score on a scale
Phase 2 N=21 Pimecrolimus Cream for Oral Lichen Planus
Oral Lichen Planus
Primary: The Primary Efficacy Variable Was the Change in the Investigator's Global Assessment of the Overall Severity of Disease From Baseline to Week 6. — 2.4; 2.45; 1.6; 2.27…
Phase 2 N=4 CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis
Candidiasis, Chronic Mucocutaneous
Primary: Clinical Response to Treatment of Mucocutaneous Candidiasis — 4 Participants
Phase 2 N=50 Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen
Cutaneous Leishmaniasis
Primary: Sensitizing Effects of LtSTA in Leishmania Naive Adults — 8; 22; 9 participants
Phase 3 N=578 Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients
HIV Infections
Primary: Clinical Cure (Defined as a Complete Resolution of Signs and Symptoms) After 14 Days of Treatment at the Test of Cure Visit (Day 17-Day 22) Using Murray Scoring Scale…
Phase 2 N=120 A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267)
Chagas Disease
Primary: Percentage of Participants With a Successful Response as Measured by Qualitative Polymerase Chain Reaction — 15.6; 10.0; 82.1; 86.7 Percentage of participants
Phase 2 N=24 Dexamethasone Solution for the Treatment of Oral Lichen Planus
Lichen Planus
Primary: Change in Oral Sensitivity — -4.5; -6.0 score on a scale
Phase 2 N=24 Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
Mucosal Melanoma · Acral/Lentiginous Melanoma · Chronically Sun Damaged Melanomas
Primary: Best Overall Response — 0; 0; 0; 7 participants
N/A N=1 Intravesical Liposomes for Ulcerative Cystitis
Interstitial Cystitis
Primary: Change in Symptom and Problem Severity — 22; 13 units on a scale
Phase 2 N=48 Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue
Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Primary: Objective Responses in Patients With MALT Lymphoma Presenting With Measureable Disease — 25; 20; 1 Participants
Phase 3 N=94 Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients
Squamous Cell Carcinoma of Nasopharynx · Squamous Cell Carcinoma of Oropharynx · Squamous Cell Carcinoma of Hypopharynx
Primary: Incidence and / or Severity of Oral Mucositis — 19; 3 Grade 3-4 oral mucositis — p=0.05
Phase 2 N=5 A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent Chemotherapy
Mucositis · Head and Neck Cancer
Primary: Number of Participants With Adverse Events (AEs) — 2; 3; 0; 2 participants